Trident Lifeline's Stake in Subsidiary Trident Mediquip Reduces to 59.47% After Private Placement
Trident Lifeline Limited's shareholding in subsidiary Trident Mediquip Limited decreased to 59.47% from 59.77% following a private placement of equity shares to other shareholders. Trident Mediquip Limited, operating in the pharmaceuticals industry, has a paid-up share capital of Rs. 9,86,58,000 and reported a turnover of 21.29 crore. The transaction was conducted on an arm's length basis and involved related party considerations due to common promoter group interests.

*this image is generated using AI for illustrative purposes only.
Trident Lifeline Limited has informed the stock exchanges about a change in its subsidiary shareholding structure following a private placement transaction by Trident Mediquip Limited. The disclosure was made under Regulation 30 of SEBI (LODR) Regulations, 2015 on April 17, 2026.
Shareholding Change Details
The company's stake in its subsidiary Trident Mediquip Limited has been reduced due to the private placement of equity shares to other shareholders. The shareholding change reflects a dilution in the parent company's ownership percentage.
| Parameter: | Details |
|---|---|
| Pre-holding: | 59.77% |
| Post-holding: | 59.47% |
| Transaction Type: | Private Placement |
| Date of Disclosure: | April 17, 2026 |
About Trident Mediquip Limited
Trident Mediquip Limited (CIN: U33309GJ2019PLC110421) is a subsidiary company incorporated under the Companies Act, 2013, with its registered office in Surat, Gujarat. The company operates in the pharmaceuticals and chemical industry.
| Financial Details: | Amount/Quantity |
|---|---|
| Authorized Share Capital: | Rs. 10,00,00,000 |
| Paid-up Share Capital: | Rs. 9,86,58,000 |
| Number of Equity Shares: | 98,65,800 shares |
| Face Value per Share: | Rs. 10 |
| Current Turnover: | 21.29 Cr |
Historical Performance
The subsidiary has shown varying performance over the past three years in terms of turnover:
| Financial Year: | Turnover |
|---|---|
| 2022-23: | 28.77 Cr |
| 2023-24: | 20.58 Cr |
| 2024-25: | 21.29 Cr |
Related Party Transaction
The transaction qualifies as a related party transaction since Trident Mediquip Limited is a subsidiary of Trident Lifeline Limited. Several promoter group members, including Mr. Amit Bhupendra Halvawala, Mr. Chetan Chandrakant Jariwala, and Mr. Hardik Jigishkumar Desai, have interests in both entities. The company has confirmed that the transaction was conducted on an arm's length basis.
Regulatory Compliance
The disclosure was made in compliance with SEBI regulations and the SEBI Master Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026. No governmental or regulatory approvals were required for this transaction, and no cash consideration or share swap was involved from the parent company's perspective.
Historical Stock Returns for Trident Lifeline
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| +0.18% | +0.60% | +3.69% | -16.68% | -3.64% | +131.11% |
What strategic initiatives is Trident Mediquip planning that required this private placement funding, and how might they impact future revenue growth?
Will the new shareholders in Trident Mediquip bring industry expertise or partnerships that could help reverse the declining turnover trend from 2022-23 levels?
How might this dilution affect Trident Lifeline's dividend income from its subsidiary and overall consolidated financial performance?


































